Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regeneron stock with a target price of $732.61, indicating potential growth.
Financial Health
Regeneron is achieving strong revenue and profit margins, indicating solid financial performance.
Dividend
Regeneron's low dividend yield of 0.15% indicates minimal income from dividends. If you invested $1000 you would be paid $1.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring REGN
Obesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
argenx SE
argenx is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of severe autoimmune diseases and cancer.
